Research Articles (Dermatology)
Permanent URI for this collection
Browse
Browsing Research Articles (Dermatology) by Author "Jordaan, H. F."
Now showing 1 - 5 of 5
Results Per Page
Sort Options
- ItemAcute febrile neutrophilic dermatosis (Sweet's syndrome). A report of 2 cases(Health & Medical Publishing Group, 1989-04) Jordaan, H. F.; De Goede, F. H.; Sandler, M.ENGLISH ABSTRACT: Two cases of Sweet's syndrome are described. The diagnostic criteria, clinical spectrum, complications, pertinent differential diagnoses and treatment modalities of this relatively rare clinical condition are described. The association of Sweet's syndrome with underlying haematological malignant disease is stressed.
- ItemClinical and pathological features of acral melanoma in a South African population : a retrospective study(Health & Medical Publishing Group, 2018-08-28) De Wet, J.; Tod, B.; Visser, W. I.; Jordaan, H. F.; Schneider, J. W.Background. Acral melanoma (AM) is a rare subtype of cutaneous melanoma (CM) that disproportionately affects skin of colour and carries a poorer prognosis than other melanoma subtypes. The poor prognosis is attributed to late diagnosis and subsequent relatively high Breslow thickness, but also to an intrinsic biological aggressiveness. Scientific data on AM from the developing world are limited and a need exists to characterise the disease further in the South African (SA) population. Objectives. To describe the clinical and pathological features of AM in an SA population. Methodology. A retrospective chart review characterised the demographics, clinical features and histological data of 66 patients diagnosed with AM between January 2010 and June 2016 at Tygerberg Academic Hospital, Cape Town, SA. Results. Sixty-six patients with AM were identified from 335 patients diagnosed with CM during the set time frame. The mean age (standard deviation (SD)) was 61.5 (12.5) years. Forty-two (63.6%) of the patients were female (male/female ratio 1:1.75). The majority of patients diagnosed with AM were black (48.5%), and the proportion of AM in black patients with CM was 80.0%. Fifty-six AMs (84.8%) were located on the foot and 10 (15.2%) on the hand. The median duration of the lesion before diagnosis was 10 months (range 2 - 84) and the mean (SD) tumour size was 3.8 (2.2) cm at diagnosis. The mean Breslow thickness of all AMs at diagnosis was 5.2 mm (median 4.2 mm, range 0 - 22). Stage of disease was known in 41 patients, 23 (56.1%) of whom had at least stage III disease at diagnosis. Mean Breslow thickness for foot and hand melanomas was 4.9 mm (range 0 - 22) and 6.9 mm (range 0 - 13.3), respectively (p=0.2552). The mean Breslow thickness in the black population was 6.3 mm compared with 4.2 mm and 4.3 mm, respectively, in the white and coloured populations (p=0.178). Patients from outside the Western Cape Province (WC) presented with a mean Breslow thickness of 6.6 mm (range 0 - 14.5) and patients from the WC with a mean Breslow thickness of 4.9 mm (range 0 - 22) (p=0.3602). Conclusions. AMs accounted for a significant proportion of all CMs diagnosed. Patients presented with an advanced stage of disease at diagnosis, and further studies are needed to further investigate the reasons for delayed diagnosis.
- ItemGuideline on the management of psoriasis in South Africa(Health and Medical Publishing Group (HMPG), 2010-04) Raboobee, N.; Aboobaker, J.; Jordaan, H. F.; Sinclair, W.; Smith, J. M.; Todd, G.; Weiss, R.; Whitaker, D.Background. Psoriasis vulgaris is a chronic, relapsing, immunemediated, potentially devastating disease, influenced by genetic and environmental factors, that can cause substantial morbidity and psychological stress and have a profound negative impact on patient quality of life. Objective. These guidelines for the management of psoriasis have been developed in an attempt to improve the outcomes of treatment of this condition in South Africa. Psoriasis has a major impact on the quality of life of sufferers, and it is expected that these guidelines, if implemented, will play a role in achieving improved outcome. Scope. These guidelines were developed to address the diagnosis and treatment of psoriasis, of differing degrees of severity and in patients of all ages, by all health care professionals involved with its management. Recommendations. All health care workers involved in the management of psoriasis should take note of these guidelines and try to implement them in clinical practice as far as possible. All treatment methods and procedures not substantiated by evidence from the literature should be discontinued and avoided to decrease the financial burden of psoriasis treatment. Validation. These guidelines were developed through general consensus by a group of 8 South African dermatologists (the ’Working Group’) sanctioned by the Dermatological Society of South Africa (DSSA), by adaptation for the South African situation of the current guidelines used in the USA, the UK, Germany, Canada and Finland. Draft documents were made available for comment to the dermatological community as a whole via the official website of the DSSA, and the guidelines were presented and discussed at the annual congress of the DSSA in 2008. All input from these sources, where appropriate, were then incorporated into these guidelines. Guidelines sponsor. Schering-Plough initiated the project and sponsored the meetings of the working group and all costs generated by these meetings. Plans for guideline revision. The field of biologicals and cytokine modulators is in a rapid phase of development, and revision of the scope and content of these guidelines will be ongoing as longer-term data emerge.
- ItemPyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab(University of California, 2017) De Wet, J.; Jordaan, H. F.; Kannenberg, S. M.; Tod, B.; Glanzmann, B.; Visser, W. I.PASH syndrome (pyoderma gangrenosum, acne, and suppurative hidradenitis) forms part of the spectrum of autoinflammatory diseases. We report an unusual case of PASH syndrome in a patient with end-stagerenal disease (ESRD) who was successfully treated with the tumor necrosis factor inhibitor, adalimumab. The case underscores the challenges associatedwith the treatment of PASH syndrome as well as the ongoing search to establish a genetic basis for the syndrome. Renal impairment has been reported in association with pyoderma gangrenosum but has notbeen described in PASH syndrome. We believe this to be the first reported case of a patient who developed PASH syndrome in the setting of ESRD.
- ItemWidespread superficial thrombophlebitis as a manifestation of secondary syphilis - a new sign. A report of 2 cases(Health & Medical Publishing Group, 1986-10) Jordaan, H. F.ENGLISH ABSTRACT: Two patients with serologically proven secondary syphilis also showed multifocal superficial thrombophlebitis. All manifestations cleared when appropriate antisyphilitic treatment was instituted. Although Treponema pallidum could not be demonstrated in the thrombophlebitic veins, the organism was considered responsible, either directly or indirectly. Multifocal superficial thrombophlebitis should be regarded as a new sign of secondary syphilis.